Oral Health and Use of Novel Transbuccal Drug Delivery Systems in Patients with Alzheimer’s and Parkinson’s Disease: A Review

Neurodegenerative disorders, such as Alzheimer’s disease (AD) and Parkinson’s (PD), are common age-related diseases responsible for high disability. Disease-modifying treatments AD PD still lacking, but symptomatic therapies available, although limited by difficult administration patients’ scarce compliance at later stages. Transbuccal Drug Delivery Systems (TDDSs) include chemical-physics biotechnologies mechatronic approaches, allowing drug delivery via the transbuccal route, a strategy that may theoretically overcome limitations imposed conventional oral administration. In this review, we provided snapshot of TDDSs, their mechanism action, existing subtypes, potential application in patients. We found variety including tablets, solutions, sprays, patches, more sophisticated “mechatronic” IntelliDrug OraFuse devices using system pumps valves continuous release. Several trials have been conducted either on models or patients to test safety efficacy antidementia antiparkinsonian agents delivered which produced encouraging results suggest future larger scale. Moreover, health has emerged fundamental prerequisite successful use TDDSs. Accordingly, greater attention hygiene is now due with neurodegenerative disease.